A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Immunoglobulin G (IgG) has an unusually long serum half-life in comparison to proteins of a similar size. It is well-known that this phenomenon is due to IgG's ability to bind the neonatal Fc receptor (FcRn) in a pH-dependent manner. FcRn binding properties can vary among IgGs, resulting in altered in vivo half-lives, and therefore it would be beneficial to accurately predict the FcRn binding properties of therapeutic IgG monoclonal antibodies (mAbs). Here we describe the development of an in vitro model capable of predicting the in vivo half-life of human IgG. Using a high-throughput biolayer interferometry (BLI) platform, the human FcRn association rate at acidic pH and subsequent dissociation rate at physiological pH was determined for 5 human IgG1 mAbs. Comparing the combined FcRn association and dissociation rates to the Phase 1 clinical study half-lives of the mAbs resulted in a strong correlation. The correlation was also verified in vivo using mice transgenic for human FcRn. The model was used to characterize various factors that may influence FcRn-mAb binding, including mAb variable region sequence differences and constant region glycosylation patterns. Results indicated that the complementarity-determining regions of the heavy chain significantly influence the mAb's FcRn binding properties, while the absence of glycosylation does not alter mAb-FcRn binding. Development of this high-throughput FcRn binding model could potentially predict the half-life of therapeutic IgGs and aid in selection of lead candidates while also serving as a screening tool for the development of mAbs with desired pharmacokinetic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 2×
“However, the ability for mAbs of the immunoglobulin G (IgG) isotype to bind the neonatal Fc receptor (FcRn) in a pH-dependent manner is the critical property associated with an IgG’s linear kinetic profile and extends the half-life of a typical IgG1 to, on average, 21 d.(26-28) Functional FcRn, a heterodimeric complex…”
BackgroundLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 1×
“PK properties are often critical to the success of a therapeutic, and recent reports have suggested »15% of Phase 1 clinical studies fail due to inadequate PK or pharmacodynamics properties.(70) This is especially true for antibodies, where typically longer halflives are desired for therapeutics to decrease dosing fre…”
BackgroundEngineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · cited 2×
“The details of this mechanism have been widely investigated.(26,37-39) It is now well known that circulating IgGs are internalized by fluid phase pinocytosis and bind membrane-bound FcRn inside the acidified sorting endosomal compartments.”
BackgroundRobbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Reduced elimination of IgG antibodies by engineering the variable region
Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265 · cited 1×
“Aside from target-mediated clearance, which contributes to non-linear PK profiles and has limited opportunity for modulation,(14-16) the properties affecting linear and non-linear kinetics may include charge variation, nonspecific binding, size, delivery route, immunogenicity, post-translational modifications, hydroph…”
BackgroundStructural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259 · cited 1×
“Elucidation of the crystal structure of FcRn(40-42) provided a means to investigate the IgG pH-dependent binding properties in detail and, as a result, a number of studies have defined the critical amino acid contacts.(43-47) More recently, mutations in these residues have exemplified the complex binding relationship…”
BackgroundEvidence to support the cellular mechanism involved in serum IgG homeostasis in humans
Ward, E. S. (2003) · International Immunology · doi:10.1093/intimm/dxg018 · Cited by 216 · cited 1×
“Later, FcRn expression in the vascular endothelium and bone marrow-derived cells was attributed to the mechanism for IgG recycling and protection from lysosomal degradation.(33-36) The details of this mechanism have been widely investigated.”
BackgroundAntohe, F., Rădulescu, L., Gafencu, A., Gheţie, V., & Simionescu, M. (2001) · Human Immunology · doi:10.1016/s0198-8859(00)00244-5 · Cited by 175
Cited by
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Structure, heterogeneity and developability assessment of therapeutic antibodies
Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1553476 · Cited by 264
Biolayer interferometry and its applications in drug discovery and development
Jug, A., Bratkovič, T., & Ilaš, J. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117741 · Cited by 107
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
Liu, C., Kim, Y. S., Lowe, J. H.-N., & Chung, S. (2021) · Bioanalysis · doi:10.4155/bio-2021-0099 · Cited by 8
Metadata
- Authors
- Souders, C. A., Nelson, S. C., Wang, Y., Crowley, A. R., Klempner, M. S., & Thomas, W.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2015-05-27
- Volume
- 7
- Issue
- 5
- Pages
- 912-921
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W1516155954
- Cited by
- 44
- References
- 9
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. https://app.cochat.ai/papers/10.1080/19420862.2015.1054585
- The paper
- Souders, C. A., Nelson, S. C., Wang, Y., Crowley, A. R., Klempner, M. S., & Thomas, W. (2015). A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. mAbs. https://doi.org/10.1080/19420862.2015.1054585
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.